Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Endometrial Neoplasms × ixabepilone × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Neoplasm Metastasis 2 Pain 1 Neoplasms 1 Endometrial Neoplasms 1 Carcinoma 1

Interventions

Paclitaxel 23 Doxorubicin 15 Carboplatin 12 pembrolizumab 7 Cisplatin 7 Radiotherapy 6 Chemotherapy, Adjuvant 5 Taxes 4 Filgrastim 4 Docetaxel 4 Brachytherapy 4 Observation 3 trastuzumab deruxtecan 2 olaparib 2 lenvatinib 2 durvalumab 2 Tamoxifen 2 Specimen Handling 2 Ifosfamide 2 Drug Therapy 2 sintilimab 1 selinexor 1 sacituzumab govitecan 1 pertuzumab 1 nanocis 1 liposomal doxorubicin 1 ixabepilone 1 gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 dostarlimab 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00883116 2017-03-09

IXAMPLE2

R-Pharm

Phase 3 Terminated

551 enrolled 13 charts

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡